NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $1.36 -0.02 (-1.09%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Opus Genetics alerts:Sign Up Key Stats Today's Range$1.35▼$1.4450-Day Range$0.99▼$1.4152-Week Range$0.65▼$1.75Volume114,481 shsAverage Volume515,079 shsMarket Capitalization$81.77 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 48% of companies evaluated by MarketBeat, and ranked 644th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingOpus Genetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialOpus Genetics has a consensus price target of $7.33, representing about 441.2% upside from its current price of $1.36.Amount of Analyst CoverageOpus Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.22) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.24% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.24% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media3.3 / 5News Sentiment0.87 News SentimentOpus Genetics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Opus Genetics this week, compared to 2 articles on an average week.Search Interest2 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Opus Genetics is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesOpus Genetics reports inducement grant under Nasdaq listing rulesSeptember 12 at 11:51 AM | msn.comOpus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 12 at 8:00 AM | globenewswire.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 15 at 2:00 AM | Stansberry Research (Ad)Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under ...September 4, 2025 | finance.yahoo.comOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast ConditionsSeptember 4, 2025 | globenewswire.comOpus Genetics Appoints New Chief Financial OfficerSeptember 3, 2025 | msn.comOpus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comOpus Genetics Appoints Rob Gagnon as Chief Financial OfficerSeptember 2, 2025 | globenewswire.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $1.19 on January 1st, 2025. Since then, IRD stock has increased by 13.9% and is now trading at $1.3550. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) announced its earnings results on Wednesday, August, 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.13. The company earned $2.88 million during the quarter, compared to analysts' expectations of $4.27 million. Opus Genetics had a negative net margin of 377.89% and a negative trailing twelve-month return on equity of 384.33%. Who are Opus Genetics' major shareholders? Top institutional shareholders of Opus Genetics include BIOS Capital Management LP (6.17%), Nantahala Capital Management LLC (5.61%), Opaleye Management Inc. (2.04%) and Mink Brook Asset Management LLC (2.01%). View institutional ownership trends. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2025Today9/15/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Price Target for Opus Genetics$7.33 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+431.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.53 million Net Margins-377.89% Pretax Margin-377.89% Return on Equity-384.33% Return on Assets-148.90% Debt Debt-to-Equity Ratio0.06 Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual Sales$10.99 million Price / Sales7.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book6.57Miscellaneous Outstanding Shares59,910,000Free Float55,954,000Market Cap$82.68 million OptionableN/A Beta0.07 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:IRD) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts